Clinical Targeted Next-Generation Panel Sequencing Reveals MYC Amplification Is a Poor Prognostic Factor in Osteosarcoma
JCO Precision Oncology · 2023-03 · (7)
DOI: 10.1200/po.22.00334 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Precision Oncology, 2023-03. Verfasst von Amanda E Marinoff und 30 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Oncology, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA. Hauptthemen laut MEDLINE: Bone Neoplasms, Osteosarcoma. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
PURPOSE Osteosarcoma risk stratification, on the basis of the presence of metastatic disease at diagnosis and histologic response to chemotherapy, has remained unchanged for four decades, does not include genomic features, and has not facilitated treatment advances. We report on the genomic features of advanced osteosarcoma and provide evidence that genomic alterations can be used for risk stratification. MATERIALS AND METHODS In a primary analytic patient cohort, 113 tumor and 69 normal samples from 92 patients with high-grade osteosarcoma were sequenced with OncoPanel, a targeted next-generation sequencing assay. In this primary cohort, we assessed the genomic landscape of advanced disease and evaluated the correlation between recurrent genomic events and outcome. We assessed whether prognostic associations identified in the primary cohort were maintained in a validation cohort of 86 patients with localized osteosarcoma tested with MSK-IMPACT. RESULTS In the primary cohort, 3-year overall survival (OS) was 65%. Metastatic disease, present in 33% of patients at diagnosis, was associated with poor OS ( P = .04). The most frequently altered genes in the primary cohort were TP 53, RB1, MYC, CCNE1, CCND3, CDKN2A/B, and ATRX. Mutational signature 3 was present in 28% of samples. MYC amplification was associated with a worse 3-year OS in both the primary cohort ( P = .015) and the validation cohort ( P = .012). CONCLUSION The most frequently occurring genomic events in advanced osteosarcoma were similar to those described in prior reports. MYC amplification, detected with clinical targeted next-generation sequencing panel tests, is associated with poorer outcomes in two independent cohorts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Pediatric Oncology, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA.
- Harvard Medical School, Boston, MA.
- Pediatric Hematology/Oncology, UCSF Benioff Children's Hospital, San Francisco, CA.
- Broad Institute of Harvard and MIT, Boston, MA.
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
- Pritzker School of Medicine, Biological Sciences Division, The University of Chicago, Chicago, IL.
ORCID-Profile: Liam F Spurr, Christina Fong, Suzanne J Forrest, Laura Corson, Audrey Mauguen, Navin Pinto, Luke Maese, Susan Colace, Margaret E Macy, Amit J Sabnis, Mark A Applebaum, Theodore W Laetsch, Julia Glade-Bender, Daniel A Weiser, Brian D Crompton, Paul Meyers, Ahmet Zehir, Laura MacConaill, Jonathan A Nowak, Marc Ladanyi, Alanna J Church, Andrew D Cherniack, Neerav Shukla, Katherine A Janeway
Förderung
- NCI NIH HHS
Zitieren
APA
Marinoff, A. E., Spurr, L. F., Fong, C., Li, Y. Y., Forrest, S. J., Ward, A., Doan, D., Corson, L., Mauguen, A., Pinto, N., Maese, L., Colace, S., Macy, M. E., Kim, A., Sabnis, A. J., Applebaum, M. A., Laetsch, T. W., Glade-Bender, J., Weiser, D. A., …, & Janeway, K. A. (2023). Clinical Targeted Next-Generation Panel Sequencing Reveals MYC Amplification Is a Poor Prognostic Factor in Osteosarcoma. JCO Precision Oncology. https://doi.org/10.1200/po.22.00334
Vancouver
Marinoff AE, Spurr LF, Fong C, Li YY, Forrest SJ, Ward A, et al. Clinical Targeted Next-Generation Panel Sequencing Reveals MYC Amplification Is a Poor Prognostic Factor in Osteosarcoma. JCO Precision Oncology. 2023. doi:10.1200/po.22.00334
BibTeX
@article{Marinoff2023,
author = {Marinoff, Amanda E and Spurr, Liam F and Fong, Christina and Li, Yvonne Y and Forrest, Suzanne J and Ward, Abigail and Doan, Duong and Corson, Laura and Mauguen, Audrey and Pinto, Navin and Maese, Luke and Colace, Susan and Macy, Margaret E and Kim, AeRang and Sabnis, Amit J and Applebaum, Mark A and Laetsch, Theodore W and Glade-Bender, Julia and Weiser, Daniel A and Anderson, Megan and Crompton, Brian D and Meyers, Paul and Zehir, Ahmet and MacConaill, Laura and Lindeman, Neal and Nowak, Jonathan A and Ladanyi, Marc and Church, Alanna J and Cherniack, Andrew D and Shukla, Neerav and Janeway, Katherine A},
title = {Clinical Targeted Next-Generation Panel Sequencing Reveals MYC Amplification Is a Poor Prognostic Factor in Osteosarcoma},
journal = {JCO Precision Oncology},
year = {2023},
number = {7},
doi = {10.1200/po.22.00334}
}
EUVIMED